Compugen (CGEN) vs Palisade Bio (PALI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Compugen (CGEN) has outperformed Palisade Bio (PALI) over the past year, gaining 20.3% versus a loss of 60.6%. Over five years, CGEN leads with a -59.5% price change compared with -100.0% for PALI. Compugen is the larger company by market cap ($174.3 million vs $150.7 million), about 1.2 times the size.
On valuation, Palisade Bio trades at a lower trailing P/E (0.9x vs 4.7x for Compugen).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEN | PALI |
|---|---|---|
| Share price | $1.84 | $0.8399 |
| Market cap | $174.29M | $150.74M |
| 1-day change | -2.13% | -9.24% |
| YTD return | +20.26% | -64.26% |
| 1-year return | +20.26% | -60.57% |
| 5-year return | -59.47% | -99.95% |
| P/E ratio (TTM) | 4.72 | 0.91 |
| EPS (TTM) | $0.39 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.76M | $0 |
| Revenue growth (YoY) | +161.14% | — |
| Net income (latest FY) | $35.34M | $-16.78M |
| Gross margin | 87.29% | — |
| Operating margin | 43.05% | — |
| Net margin | 48.57% | — |
| 52-week high | $3.24 | $2.86 |
| 52-week low | $1.43 | $0.8381 |
| Distance from 52-week high | -43.21% | -70.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +160.87% | +935.84% |
| Average volume | 223.56K | 3.19M |
| Shares outstanding | 94.72M | 179.28M |
| Employees | 75 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGEN has outperformed PALI by 80.8 percentage points over the past year.
- Compugen trades at a higher earnings multiple (4.7x vs 0.9x trailing P/E).
About Compugen
CGEN stock →Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 75 employees
About Palisade Bio
PALI stock →Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
CGEN vs PALI FAQ
Which is bigger, Compugen or Palisade Bio?
Compugen (CGEN) is larger, with a market capitalization of $174.29M compared with $150.74M for Palisade Bio (PALI).
Which stock has performed better over the past year, CGEN or PALI?
CGEN returned +20.26% over the past 12 months, compared with -60.57% for PALI (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CGEN or PALI?
PALI has the lower trailing P/E at 0.9, versus 4.7 for CGEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Compugen and Palisade Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.